Antoni Ribas, MD
Jonsson Comprehensive Cancer Center
5
1
4
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (5)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Steven A. Rosenberg, MD, PhD
NCI - Surgery Branch
Shared therapeutic areas:
Worked with same sponsors:
James S. Economou, MD
Jonsson Comprehensive Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Lizhi Niu, PhD
Fuda Cancer Hospital
Shared therapeutic areas:
Herui Yao, PhD
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Shared therapeutic areas:
Dong-Xin Wang, MD, PhD
Peking University First Hospital
Shared therapeutic areas:
Jeong Min Lee, MD
Seoul National University Hospital
Shared therapeutic areas:
Sabine Hazan, MD
ProgenaBiome
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
Averell Sherker, MD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Shared therapeutic areas:
Brennan Spiegel, MD, MSHS
Cedars-Sinai Medical Center
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (5)
Showing 5 of 5 trials
ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma
CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery
Vaccine Therapy in Treating Patients With Stage II, Stage IIIA, Stage IIIB, or Stage IVA Liver Cancer
Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma
Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma
All 5 trials loaded